Understanding and optimising patient and public involvement in trial oversight: an ethnographic study of eight clinical trials

Table 2 Randomised trials facing challenges and public contributors

Trial number	Clinical area/population	Meetings observed		Public contributors at meeting		Discussion of PPI if no contributors at meeting observed		PPI in the trial reported by interviewees, if not observed
Trial number	Clinical area/population	TSC	TMG	TSC	TMG	TSC	TMG	PPI in the trial reported by interviewees, if not observed
1	Oncology	✓	✓	0	0	x	x	On TMG, although not at meeting observed
2	Oncology	✓	x	0	–	x	–	On TMG.
3	Arthritis	✓	✓	0	0	x	✓	Previous involvement of a public member, trying to recruit a new member
4	Frailty	✓	✓	0	0	x	✓	Confusion as to whether certain trial interactions with patients counted as PPI. Patient charity representative invited to TSC meetings with poor attendance.
5	Oncology	✓	✓	0	2	x	n/a
6	Urology	✓	x	1	–	n/a	–
7	Psychology	✓	✓	1	1*	n/a	n/a
8	Oncology	✓	✓	1*	1*	n/a	n/a

PPI patient and public involvement, TMG trial management group, TSC trial steering committee, n/a not applicable, − not observed
*Public contributors interviewed. Different public contributors were present at the TMG and the TSC of both trials 7 and 8 for a total of 7 public contributors observed in meetings

ISSN: 1745-6215